Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease. It is also developing omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RETA
CUSIPN/A
Phone972-865-2219
Debt
Debt-to-Equity Ratio-0.12
Current Ratio2.62
Quick Ratio2.62
Price-To-Earnings
Trailing P/E Ratio-18.83
Forward P/E Ratio-18.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.06 million
Price / Sales20.40
Cash FlowN/A
Price / CashN/A
Book Value($5.62) per share
Price / Book-6.67
Profitability
EPS (Most Recent Fiscal Year)($1.99)
Net Income$-47,670,000.00
Net Margins-53.89%
Return on EquityN/A
Return on Assets-28.97%
Miscellaneous
Employees93
Outstanding Shares26,160,000
Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions
What is Reata Pharmaceuticals' stock symbol?
Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."
How were Reata Pharmaceuticals' earnings last quarter?
Reata Pharmaceuticals Inc (NASDAQ:RETA) issued its quarterly earnings data on Tuesday, May, 8th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.61) by $0.76. The business had revenue of $32.39 million for the quarter, compared to analysts' expectations of $10.21 million. View Reata Pharmaceuticals' Earnings History.
What price target have analysts set for RETA?
8 Wall Street analysts have issued twelve-month price targets for Reata Pharmaceuticals' stock. Their forecasts range from $43.00 to $78.00. On average, they expect Reata Pharmaceuticals' stock price to reach $54.7143 in the next twelve months. View Analyst Ratings for Reata Pharmaceuticals.
What are Wall Street analysts saying about Reata Pharmaceuticals stock?
Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (5/9/2018)
- 2. Cowen Inc analysts commented, "RETA reported 3Q17 financials yesterday, noting that the three major programs." (11/14/2017)
Who are some of Reata Pharmaceuticals' key competitors?
Some companies that are related to Reata Pharmaceuticals include Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL), HUTCHISON CHINA/S (HCM), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Supernus Pharmaceuticals (SUPN), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), Portola Pharmaceuticals (PTLA), The Medicines (MDCO), Emergent Biosolutions (EBS) and Evotec (EVTCY).
Who are Reata Pharmaceuticals' key executives?
Reata Pharmaceuticals' management team includes the folowing people:
- Mr. J. Warren Huff, Chairman, CEO & Pres (Age 64)
- Dr. Colin J. Meyer, Chief Medical Officer & VP of Product Devel. (Age 39)
- Dr. Keith W. Ward, VP & Chief Devel. Officer (Age 48)
- Mr. Jason D. Wilson, CFO & VP of Strategy (Age 48)
- Ms. Elaine Castellanos, VP of Fin. & Accounting and Principal Accounting Officer
When did Reata Pharmaceuticals IPO?
(RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.
Has Reata Pharmaceuticals been receiving favorable news coverage?
Press coverage about RETA stock has trended somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Reata Pharmaceuticals earned a news sentiment score of 0.13 on Accern's scale. They also gave news coverage about the company an impact score of 46.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Reata Pharmaceuticals' major shareholders?
Reata Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.56%), Prosight Management LP (1.14%), JPMorgan Chase & Co. (0.65%), Northern Trust Corp (0.50%), King Luther Capital Management Corp (0.24%) and Landscape Capital Management L.L.C. (0.21%). Company insiders that own Reata Pharmaceuticals stock include A/S Novo, Abbvie Inc, Colin John Meyer, Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr, Keith Wayne Ward and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals.
Which institutional investors are selling Reata Pharmaceuticals stock?
Which institutional investors are buying Reata Pharmaceuticals stock?
RETA stock was bought by a variety of institutional investors in the last quarter, including Prosight Management LP, Landscape Capital Management L.L.C., Sofinnova Ventures Inc, Citadel Advisors LLC, Stifel Financial Corp, UBS Group AG, DekaBank Deutsche Girozentrale and King Luther Capital Management Corp. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Colin John Meyer, Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals.
How do I buy shares of Reata Pharmaceuticals?
Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Reata Pharmaceuticals' stock price today?
One share of RETA stock can currently be purchased for approximately $37.48.
How big of a company is Reata Pharmaceuticals?
Reata Pharmaceuticals has a market capitalization of $1.03 billion and generates $48.06 million in revenue each year. The company earns $-47,670,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Reata Pharmaceuticals employs 93 workers across the globe.
How can I contact Reata Pharmaceuticals?
Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]
MarketBeat Community Rating for Reata Pharmaceuticals (RETA)
MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe RETA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days.
